They are prepared by licensed compounding pharmacies under physician prescription and have not been evaluated through clinical trials for safety, efficacy, or therapeutic equivalence to any FDA-approved medications
Supports Brain Function: Some studies suggest that B P C-157 can help protect neurons and potentially assist in cognitive health and recovery from traumatic brain injuries
Possible support for immune dysregulation aspects of the condition
This research blend combines a NAD + -associated coenzyme component , a mitochondria-derived peptide , and an NNMT-pathway small-molecule analog into a single laboratory formulation for investigational use
Recommended Antimicrobial Agents for Diarrhea Pathogen First choice Alternative Comments Bacteria Campylobacter Nontyphoidal Salmonella entericab Azithromycin Usually not indicated for uncomplicated infection Ciprofloxacin NA Salmonella enterica Typhi or Paratyphib Shigellaa Ceftriaxone or ciprofloxacin Ampicillin or TMP-SMX, or azithromycin TMP-SMX or ampicillin if susceptible Vibrio cholerae Doxycyclinee NonVibrio choleraee For noninvasive disease: usually not indicated, but single-agent therapy if treated For invasive disease: ceftriaxone with doxycycline TMP-SMX Ciprofloxacin, azithromycin, or ceftriaxone For noninvasive disease: usually not indicated, but single-agent therapy if treated For invasive disease: TMP-SMX with an aminoglycoside Cefotaxime or ciprofloxacin Nitazoxanide (HIV-uninfected, HIV-infected in combination with effective cART) TMP-SMX Effective cART: immune reconstitution may lead to microbiologic and clinical response Nitazoxanide (limited data) Giardia lamblia Tinidazole (data from HIV- uninfected children) Nitazoxanide Metronidazole (data from HIV-uninfected children) Cystoisospora belli TMP-SMX Trichinella spp Albendazole Pyrimethamine Potential second-line alternatives: ciprofloxacin, nitazoxanide Mebendazole a Yersinia enterocolitica Parasites Cryptosporidium spp Cyclospora cayetanensis Azithromycinc or ciprofloxacina, or ceftriaxone Antimicrobial therapy should be considered for groups at increased risk for invasive infection: neonates (3 mo old)
WASHINGTON Health advisers met Thursday to review more than a half-dozen peptides, unproven substances that have become a growing wellness trend despite little evidence they are safe or effective
